论文部分内容阅读
Ivabradine是一种If抑制剂,已被列入治疗冠心病的药物,在HOT Line栏内已报告,慢性心力衰竭(简称心衰)及心率快病人用后心血管死亡及住院明显降低。首席研究者Micheal Komagda对其结果作如下评点:慢性心衰是常见病。欧洲的该类病人达15000000,死亡率高,生活质量极差,约50%在5年内死亡。SHIFT临床试验(systolic heart failure treatment with the lfinhibitor ivabradine trial)的目的是探
Ivabradine, an If inhibitor, has been included in the treatment of coronary heart disease and has been reported in the HOT Line column. Cardiovascular death and hospitalization for chronic heart failure (CHF) and fast heart rate patients are significantly reduced. Lead investigator Micheal Komagda comments on the results as follows: Chronic heart failure is a common disease. In Europe, there are 15 million such patients, with high mortality and poor quality of life. About 50% of these patients die within 5 years. The purpose of the SHIFT clinical trial (with the lfinhibitor ivabradine trial) is to explore